Protagonist Therapeutics, Inc. — FY2017 Form 10-K Summary
Business context and reporting period
Protagonist is a clinical-stage biopharmaceutical company developing constrained peptide therapeutics. The filing covers the fiscal year ended December 31, 2017, with quarterly data also provided. The company has no approved products and has not generated product-sales revenue.
- PTG-100: Oral, GI-restricted alpha-4-beta-7 integrin antagonist in a global Phase 2b ulcerative colitis trial expected to enroll approximately 240 patients.
- PTG-200: Oral, GI-restricted IL-23 receptor antagonist; Phase 1 healthy-volunteer study began in the fourth quarter of 2017 and is being developed with Janssen.
- PTG-300: Injectable hepcidin mimetic for anemia associated with beta-thalassemia and other rare blood disorders; Phase 1 was completed in the fourth quarter of 2017.
Financial performance and liquidity
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| License and collaboration revenue | $20.1 million | $0 | New in 2017 |
| Research and development expense | $46.2 million | $25.7 million | Up 80% |
| General and administrative expense | $11.8 million | $7.0 million | Up 69% |
| Loss from operations | $(37.9) million | $(32.7) million | Loss increased $5.2 million |
| Net loss | $(37.0) million | $(37.2) million | Improved $0.2 million |
| Net loss per share | $(2.09) | $(5.80) | Improved, partly due to higher share count |
| Cash, cash equivalents and available-for-sale securities | $155.5 million | $87.7 million | Up $67.7 million |
- Operating cash flow was positive at $3.9 million, compared with $(30.0) million in 2016, primarily because of the $31.8 million increase in deferred revenue related to the Janssen agreement.
- Investing cash flow was $15.8 million, including $56.0 million of security maturities, $39.5 million of security purchases and $0.7 million of capital expenditures.
- Financing cash flow was $65.6 million, primarily from $64.5 million of net proceeds from the October-November 2017 public offering.
- The company had no outstanding debt at December 31, 2017. Total liabilities were $43.1 million, including $31.8 million of deferred revenue and $12.9 million of future operating lease obligations.
- Working capital was $108.4 million and accumulated deficit was $101.6 million.
- Management stated that existing liquidity was expected to fund operations for at least the next 12 months, but would not fund initiation of pivotal clinical trials. Additional capital is expected to be required.
Material changes versus the prior comparable period
- Janssen agreement became effective July 13, 2017. Protagonist received a non-refundable $50.0 million upfront payment and recognized $20.1 million of license and collaboration revenue during 2017; $31.8 million remained deferred at year-end.
- R&D spending increased by $20.5 million, driven by higher PTG-100 activity, initiation of PTG-200 and PTG-300 clinical programs, increased discovery spending and lower grant and incentive reimbursements.
- Headcount increased from 27 R&D employees at year-end 2016 to 44 at year-end 2017; total employees were 55.
- The company raised $64.5 million of net proceeds through a follow-on equity offering and ended 2017 with 21.1 million shares outstanding, versus 16.7 million at year-end 2016.
- Stock-based compensation increased to $4.2 million from $2.1 million.
- Previously identified material weaknesses in internal control over financial reporting were reported as remediated as of December 31, 2017. The independent auditor was not required to provide an internal-control attestation because the company remained an emerging growth company.
Guidance, outlook, risks and unusual items
- Management expected a PTG-100 interim futility analysis in the first quarter of 2018 and top-line Phase 2b results in the fourth quarter of 2018. Subject to success, pivotal development in ulcerative colitis and Crohn’s disease was anticipated to begin in 2019.
- Management expected to file a U.S. IND for PTG-300, submit related non-U.S. applications and initiate a beta-thalassemia Phase 2 study in 2018.
- Management expected to initiate IND-enabling studies for a fourth oral peptide candidate targeting a non-IBD GI condition.
- Under the Janssen agreement, Protagonist could receive a $25.0 million payment upon Phase 2 IND filing, $125.0 million and $200.0 million opt-in payments tied to later development decisions, up to $590.0 million of additional potential milestones and tiered royalties ranging from 10% to the mid-teens. These amounts were contingent and not recognized as revenue at year-end.
- Janssen may terminate the agreement for convenience. Failure by Janssen to exercise future opt-in rights could terminate the collaboration and require Protagonist to fund or re-partner PTG-200 development.
- Protagonist relies on contract research organizations and contract manufacturers and has no internal manufacturing facilities. Clinical failure, enrollment delays, regulatory action, manufacturing problems, safety findings and competition are significant risks.
- On September 26, 2017, Medical Diagnostic Laboratories sued over alleged infringement involving PTG-200. Protagonist’s motion to dismiss was granted February 7, 2018, without prejudice to potential amendment or future litigation.
- The Tax Cuts and Jobs Act resulted in a provisional $11.5 million reduction in deferred tax assets, fully offset by a valuation allowance. No income tax provision was recorded.
- Protagonist had no product revenue, no approved products and continued to expect significant losses and additional financing needs.
Important facts for investors to verify
- Progress, futility analysis and efficacy results for the PTG-100 Phase 2b trial, including enrollment and timing of top-line data.
- PTG-200 Phase 1 results, Janssen’s Phase 2 plans and the timing and probability of future opt-in payments.
- PTG-300 IND acceptance, Phase 2 initiation and clinical safety and efficacy data in beta-thalassemia patients.
- Cash-burn trends excluding the temporary benefit from Janssen deferred revenue and the company’s timing of future capital raises.
- Terms and potential consequences of Janssen termination, milestone constraints, cost-sharing obligations and future royalty arrangements.
- Status of the MDL patent matter and any further claims involving PTG-200 or related IL-23R compounds.
- Actual clinical manufacturing capacity, supply-chain redundancy and regulatory readiness as programs advance toward pivotal trials.